CGTLive®’s Weekly Rewind – February 14, 2025
Review top news and interview highlights from the week ending February 14, 2025.
CGTLive®’s Weekly Rewind
Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
1. Phase 2 Trial for BMS's Liso-Cel Meets Primary End Point in R/R Marginal Zone Lymphoma Cohort
Liso-cel showed a statistically significant and clinically meaningful overall response rate in the cohort.
2. Reena Sharma, MD, on Assessing Spur Therapeutics’ Gene Therapy FLT201 in Gaucher Disease
The adult metabolic consultant at Salford Royal Hospital discussed results she presented at the 21st Annual WORLDSymposium.
3. No Significant Reduction of CRS or ICANS Seen With Sobi's Anakinra in Patient's Receiving Liso-Cel for LBCL
The data, which comes from a phase 2 trial, were presented at the 2025 Tandem Meetings.
4. CareDx’s AlloHeme Shows Accuracy in Detecting Relapse Following AlloHSCT in AML and MDS
AlloHeme utilizes detection of increased mixed chimerism (iMC) at a threshold of 0.2% or greater in the recipient’s chimerism between 2 consecutive readings to predict relapse.
5. International Epilepsy Day 2025: Looking Back at Progress for Cell and Gene Therapy
In observance of International Epilepsy Day, held annually on the second Monday of February, we took a look back at the past year's news in cell and gene therapy for epilepsy indications.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Jeffrey Chamberlain, PhD, on the Import of Early Intervention in DMD
July 10th 2025The McCaw Endowed Chair of Muscular Dystrophy at University of Washington, discussed how comprehensive care for DMD patients involves early diagnosis, steroid treatment, consideration of mutation-specific therapies, and more.
